81068-26-0

Usage

Uses

Used in Organic Synthesis:
3-(2-Morpholin-4-ylethoxy)benzaldehyde is utilized as a key intermediate in organic synthesis for the creation of a diverse array of chemical products. Its presence of both morpholine and benzaldehyde moieties allows for a wide range of chemical reactions, making it a valuable component in the synthesis of various organic compounds.
Used in Pharmaceutical Research:
In the pharmaceutical industry, 3-(2-Morpholin-4-ylethoxy)benzaldehyde is used as a research compound for the development of new drugs and pharmaceuticals. Its unique structure and reactivity make it a promising candidate for the design and synthesis of novel therapeutic agents, potentially leading to advancements in medicinal chemistry.
Used as a Building Block for Complex Organic Molecules:
3-(2-Morpholin-4-ylethoxy)benzaldehyde is employed as a versatile building block in the construction of complex organic molecules. Its structural components, including the morpholine and benzaldehyde moieties, facilitate the formation of intricate molecular architectures, which are essential in various chemical and pharmaceutical applications.

InChI:InChI=1/C13H17NO3/c15-11-12-2-1-3-13(10-12)17-9-6-14-4-7-16-8-5-14/h1-3,10-11H,4-9H2

Upstream product

• 3240-94-6 N-(2-chlorethyl)morpholine 
• 100-83-4 meta-hydroxybenzaldehyde 
• 110-91-8 morpholine 
• 186191-19-5 m-(2-bromoethyloxy)benzaldehyde 
• 3647-69-6 4-(2-chloroethyl)morpholine hydrochride 

Downstream Products

• 1172118-34-1 2-{3-[2-(morpholino)ethoxy]phenyl}-4,5-diphenylimidazole 
• 1241507-30-1 N-(5-iodo-pyridin-2-yl)-N'-[1-[3-(2-morpholin-4-yl-ethoxy)-phenyl]-meth-(E)-ylidene]-hydrazine 
• 1616110-98-5 (Z)-2-[3-(2-morpholin-4-ylethoxy)-benzylidene]-3-oxo-2,3-dihydrobenzofuran-7-carboxamide 
• 942950-86-9 2-(4-(6-Chloro-2-(3-(2-morpholinoethoxy)phenyl)-3H-imidazo[4,5-b]pyridin-7-yl)piperazin-1-yl)-N-(thiazol-2-yl)acetamide 
• 1443252-45-6 6-fluoro-3-[3-(2-morpholin-4-ylethoxy)phenyl][1,2,4]triazolo[4,3-a]pyridine 
• 1443252-44-5 N-(5-fluoropyridin-2-yl)-N'-[1-[3-(2-morpholin-4-ylethoxy)phenyl]methylidene]hydrazine 
• 1155224-41-1 6-amino-5-[{3-(2-morpholin-4-ylethoxy)benzylidene}amino]-1,3-dimethyluracil 

Relevant academic research and scientific papers

Bronchospasmolytic activity and adenosine receptor binding of some newer 1,3-dipropyl-8-phenyl substituted xanthine derivatives

The aldehyde derivatives of 1,3-dipropyl xanthines as described in this paper, constitutes a new series of selective adenosine ligands displaying bronchospasmolytic activity. The effect of substitution at third- and fourth-position of 8-phenyl xanthine ha

COMPOUNDS FOR MODULATING DDAH AND ADMA LEVELS, AS WELL AS METHODS OF USING THEREOF TO TREAT DISEASE

Disclosed are compounds that can modulate DDAH and the amount of asymmetric dimethylarginine (ADMA) in a subject. Also provided are pharmaceutical compositions comprising these compounds, as well as methods of using these compositions to treat and/or prevent diseases associated with elevated or low levels of DDAH and ADMA.

Discovery and structure-activity relationship of novel 2,3- dihydrobenzofuran-7-carboxamide and 2,3-dihydrobenzofuran-3(2 h)-one-7-carboxamide derivatives as poly(ADP-ribose)polymerase-1 Inhibitors

Novel substituted 2,3-dihydrobenzofuran-7-carboxamide (DHBF-7-carboxamide) and 2,3-dihydrobenzofuran-3(2H)-one-7-carboxamide (DHBF-3-one-7-carboxamide) derivatives were synthesized and evaluated as inhibitors of poly(ADP-ribose) polymerase-1 (PARP-1). A structure-based design strategy resulted in lead compound 3 (DHBF-7-carboxamide; IC50 = 9.45 μM). To facilitate synthetically feasible derivatives, an alternative core was designed, DHBF-3-one-7-carboxamide (36, IC50 = 16.2 μM). The electrophilic 2-position of this scaffold was accessible for extended modifications. Substituted benzylidene derivatives at the 2-position were found to be the most potent, with 3′,4′-dihydroxybenzylidene 58 (IC50 = 0.531 μM) showing a 30-fold improvement in potency. Various heterocycles attached at the 4′-hydroxyl/4′-amino of the benzylidene moiety resulted in significant improvement in inhibition of PARP-1 activity (e.g., compounds 66-68, 70, 72, and 73; IC50 values from 0.718 to 0.079 μM). Compound 66 showed selective cytotoxicity in BRCA2-deficient DT40 cells. Crystal structures of three inhibitors (compounds (-)-13c, 59, and 65) bound to a multidomain PARP-1 structure were obtained, providing insights into further development of these inhibitors.

IMIDAZO [4, 5 - B] PYRIDINE DERIVATIVES AS ALK AND JAK MODULATORS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS

This application relates to compounds of the Formula I as defined herein, and/or salts thereof. This application further relates to compositions and methods of using these compounds and/or salts thereof. The compounds of Formula I are useful as ALK and JAK modulators for the treatment of proliferative disorders.

Synthesis and antimicrobial activity of novel analogs of trifenagrel

Novel analogs of trifenagrel were synthesized by using inexpensive and reusable phosphotungstic acid, H3[PW12O40] (3 mol %) catalyst under classical heating. Two of the newly synthesized triaryl imidazoles exhibited moderate antibacterial activity.

Synthesis of a series of 8-(substituted-phenyl)xanthines and a study on the effects of substitution pattern of phenyl substituents on affinity for adenosine A1 and A2A receptors

A new series of 8-(substituted-phenyl)xanthines have been synthesized and compounds were evaluated for their affinity for A1 and A2 adenosine receptors (AR) using radioligand binding assays. The effects of varying the positions of 8-phenyl substituents on affinity and selectivity at A1 and A2A adenosine receptors have been studied. Isovanilloid 1,3-dimethyl-8-[4-methoxy-3-(2-morpholin-4-ylethoxy)phenylxanthine (9d) displayed the highest affinity and selectivity towards A2A AR subtypes with Ki = 100 nM over A1 receptors (Ki > 100 mM). It has been observed that substitution pattern on 8-phenyl group greatly affects the affinity and selectivity at adenosine receptors, with A2A tolerating bulkier substituents than did A1 receptors.

Compounds for the treatment of ischemia

A3 agonists, methods of using such A3 agonists and pharmaceutical compositions containing such A3 agonists. The A3 agonists are useful for the reduction of tissue damage resulting from tissue ischemia or hypoxia

Butenolide endothelin antagonists with improved aqueous solubility

Continued development around our ET(A)-selective endothelin (ET) antagonist 1 (CI-1020) has led to the synthesis of analogues with improved aqueous solubility profiles. Poor solubility characteristics displayed by 1 required a complex buffered formulation